Stress Granule Dysfunction Validation in Parkinson's Disease

SUMMARY

# Stress Granule Dysfunction Validation in Parkinson's Disease ## Background and Rationale Stress granules are ribonucleoprotein complexes that form during cellular stress to protect mRNAs and regulate translation. Recent evidence suggests that stress granule dysfunction may contribute to alpha-synuclein aggregation and neurodegeneration in Parkinson's Disease (PD). Alpha-synuclein, the primary component of Lewy bodies in PD, can interact with stress granule proteins and potentially disrupt thei

METHODOLOGY NOTES

Phase 1 (Months 1-6): Recruit 50 PD patients and 25 age-matched controls. Collect CSF and plasma samples via standardized protocols. Extract postmortem substantia nigra tissue from 20 PD cases and 15 controls from brain banks. Phase 2 (Months 7-12): Perform immunofluorescence staining for stress granule markers (G3BP1, TIA1, PABP1) and alpha-synuclein in tissue sections using confocal microscopy. Quantify co-localization using Pearson correlation coefficients. Phase 3 (Months 13-18): Generate iPSC-derived dopaminergic neurons from 15 PD patients and 10 controls. Induce oxidative stress using 200μM sodium arsenite for 1-4 hours. Monitor stress granule formation and dissolution kinetics using live-cell imaging. Phase 4 (Months 19-24): Measure stress granule proteins and alpha-synuclein in patient biofluids using ELISA and Simoa platforms. Perform RNA sequencing on stress granule-enriched fractions from iPSC neurons to identify dysregulated transcripts. Statistical analysis using ANOVA wi